Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R130 in Advanced Bone and Soft Tissue Tumors
NCT06171282Phase 1Recruiting
- Sponsor
- Shanghai Yunying Medical Technology Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R130 in osteosarcoma (OS), sarcoma, soft tissue sarcoma (STS) and 1 more, sponsored by Shanghai Yunying Medical Technology Co., Ltd. Primary endpoints: Subject incidence of adverse events at 6 months, Subject incidence of laboratory abnormalities at 1 month and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
R130
03
Conditions
osteosarcoma (OS)sarcomasoft tissue sarcoma (STS)Bone tumor (BT)
Beyond the preview
Go deeper on NCT06171282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171282.